Tempus announces the national launch of fda-approved xt cdx test

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced the national launch of the company's fda-approved, ngs-based in vitro diagnostic device, xt cdx. beginning today, xt cdx is now available for all ordering clinicians nationwide. xt cdx is a fda-approved test that delivers comprehensive insights with one of the largest reported gene panels available. xt cdx is a 648-gene next-gen.
TEM Ratings Summary
TEM Quant Ranking